CABLIVI (Sanofi-Aventis Australia Pty Ltd)
Product name
CABLIVI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
104 working days (120)
Active ingredients
caplacizumab
Registration type
NCE/NBE
Indication
CABLIVI (powder for injection) is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.